Corrective information regarding the Annual Report 2024 and the Interim Report for H1 2025 following an order from the Danish Business Authority

About this update from Pharma Equity Group A/s Class A

[{"type":"image","alt":"Pharma Equity Group A/S","displaySize":"","headline":null,"caption":"Pharma Equity Group A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PTz7GpCf_hKeFTaw0Xo7Fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c","width":300,"height":34}},"lazy":false},{"type":"text","content":"Corrective information regarding the Annual Report 2024 and the Interim Report for H1 2025 following an order from the Danish Business Authority","length":144,"tagName":"p"},{"type":"text","content":"Copenhagen, 26 November 2025","length":28,"tagName":"p"},{"type":"text","content":"Company Announcement no. 12","length":27,"tagName":"p"},{"type":"text","content":"Pharma Equity Group A/S ("the Company") hereby publishes the consequences of a correction to the Company's Annual Report for 2024 and Interim Report for the first half of 2025.","length":190,"tagName":"p"},{"type":"text","content":"This company announcement is issued following an order from the Danish Business Authority dated 20 November 2025 in case no. 2024-5542. The Authority has ordered the Company to apply an "Expected Credit Loss" (ECL) model in accordance with IFRS 9 for the measurement of the Company's receivable from Portinho S.A.","length":327,"tagName":"p"},{"type":"text","content":"Publication of formal supplement","length":32,"tagName":"p"},{"type":"text","content":"The Company's auditor, BDO Statsautoriseret Revisionsaktieselskab, has commenced the review of the corrective information for the purpose of issuing an auditor's report. The Company expects to publish the final, audited supplement to the annual report ("Supplementary Information"), including the independent auditor's report, within approximately 14 days.","length":378,"tagName":"p"},{"type":"text","content":"The tables below show the financial consequences that will appear in the final supplement.","length":90,"tagName":"p"},{"type":"text","content":"Background","length":10,"tagName":"p"},{"type":"text","content":"The Company has previously measured the receivable based on a simplified net present value approach. In compl...

More updates from Pharma Equity Group A/s Class A